What is Medeia?
Medeia Inc operates at the intersection of advanced biometrical software and diagnostic hardware, providing critical infrastructure for neurology, cardiology, and primary care practitioners. The company's core offerings, including the BrainView NeuralScan and the VitalScan series, facilitate precise neuro-cognitive assessments and heart rate variability monitoring. By bridging the gap between complex physiological data and actionable clinical insights, Medeia serves a broad spectrum of medical professionals, researchers, and educational institutions. Their long-standing presence in the market reflects a deep-seated commitment to technical precision and the evolution of diagnostic standards in modern healthcare.
How much funding has Medeia raised?
Medeia has raised a total of $1.6M across 2 funding rounds:
Other Financing Round
$1.5M
Debt
$150K
Other Financing Round (2007): $1.5M with participation from Brook Venture Partners
Debt (2020): $150K led by PPP
Key Investors in Medeia
Brook Venture Partners
A venture capital firm, now operating as 424 Capital, that specializes in providing growth capital and strategic partnership to expansion-stage technology and healthcare businesses.
PPP
Public-Private Partnership
What's next for Medeia?
With the recent infusion of capital, Medeia is well-positioned to accelerate its research and development initiatives, particularly in the integration of AI-driven analytics within its existing diagnostic hardware ecosystem. The strategic focus will likely shift toward scaling the distribution of its neuro-cognitive assessment tools to meet the rising demand for non-invasive monitoring solutions in primary care settings. As the company moves into this next phase of growth, the emphasis will remain on enhancing the interoperability of its software platforms, ensuring that clinicians can seamlessly integrate physiological data into broader patient management workflows. This strategic expansion is expected to fortify Medeia's competitive advantage in the global medical device market.
See full Medeia company page
